Valentina Agostoni
University of Paris-Sud
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Valentina Agostoni.
Advanced Healthcare Materials | 2013
Valentina Agostoni; Tamim Chalati; Patricia Horcajada; Hervé Willaime; Resmi Anand; Nicolas Semiramoth; Tarek Baati; Shaun Hall; Guillaume Maurin; Hélène Chacun; Kawthar Bouchemal; Charlotte Martineau; Francis Taulelle; Patrick Couvreur; Christine Rogez-Kreuz; Pascal Clayette; Sandra Monti; Christian Serre; Ruxandra Gref
Nanoscale mesoporous iron carboxylates metal-organic frameworks (nanoMOFs) have recently emerged as promising platforms for drug delivery, showing biodegradability, biocompatibility and important loading capability of challenging highly water-soluble drugs such as azidothymidine tryphosphate (AZT-TP). In this study, nanoMOFs made of iron trimesate (MIL-100) were able to act as efficient molecular sponges, quickly adsorbing up to 24 wt% AZT-TP with entrapment efficiencies close to 100%, without perturbation of the supramolecular crystalline organization. These data are in agreement with molecular modelling predictions, indicating maximal loadings of 33 wt% and preferential location of the drug in the large cages. Spectrophotometry, isothermal titration calorimetry, and solid state NMR investigations enable to gain insight on the mechanism of interaction of AZT and AZT-TP with the nanoMOFs, pointing out the crucial role of phosphates strongly coordinating with the unsaturated iron(III) sites. Finally, contrarily to the free AZT-TP, the loaded nanoparticles efficiently penetrate and release their cargo of active triphosphorylated AZT inside major HIV target cells, efficiently protecting against HIV infection.
Journal of Physical Chemistry B | 2014
Resmi Anand; Francesco Borghi; Francesco Manoli; Ilse Manet; Valentina Agostoni; Pierluigi Reschiglian; Ruxandra Gref; Sandra Monti
Doxorubicin (DOX) entrapment in porous Fe(III)-trimesate metal organic frameworks (MIL-100(Fe)) nanoparticles was investigated in neutral Tris buffer via UV-vis absorption, circular dichroism (CD), and fluorescence. The binding constants and the absolute spectra of the DOX-MIL-100(Fe) complexes were determined via absorption and fluorescence titrations. A binding model where DOX associates as monomer to the dehydrated Fe3O (OH)(H2O)2 [(C6H3)(CO2)3]2 structural unit in 1:1 stoichiometry, with apparent association constant of (1.1 to 1.8) × 10(4) M(-1), was found to reasonably fit the experimental data. Spectroscopic data indicate that DOX binding occurs via the formation of highly stable coordination bonds between one or both deprotonated hydroxyl groups of the aglycone moiety and coordinatively unsaturated Fe(III) centers. Complete quenching of the DOX fluorescence and remarkable thermal and photochemical stability were observed for DOX incorporated in the MIL-100(Fe) framework.
Journal of Materials Chemistry B | 2013
Valentina Agostoni; Resmi Anand; Sandra Monti; Shaun Hall; Guillaume Maurin; Patricia Horcajada; Christian Serre; Kawthar Bouchemal; Ruxandra Gref
Encapsulation of azidothymidine (AZT) or its phosphorylated derivatives (AZT-MP and AZT-TP) has been performed using nanoparticles of the porous crystalline iron(iii) trimesate metal-organic framework MIL-100(Fe). The number of phosphate groups per nucleoside analogue has a high impact on the drug loading capacity, and their interaction with the Lewis acid sites from the nanoMOFs is also discussed through a combination of techniques such as UV-vis absorption, circular dichroism, isothermal titration calorimetry, HPLC and molecular simulations. Finally, the effect of the differences in terms of host-guest interactions is discussed through the release in physiological buffers of AZT, AZT-MP and AZT-TP. New perspectives for the nanoencapsulation of monophosphorylated nucleoside analogues for effective anti-cancer and anti-viral therapies are then discussed.
Journal of Materials Chemistry B | 2017
M. T. Marcos-Almaraz; Ruxandra Gref; Valentina Agostoni; C. Kreuz; P. Clayette; Christian Serre; Patrick Couvreur; Patricia Horcajada
The efficacy of the routinely used anti-HIV (Human Immunodeficiency Virus) therapy based on nucleoside reverse transcriptase inhibitors (NRTIs) is limited by the poor cellular uptake of the active triphosphorylated metabolites and the low efficiency of intracellular phosphorylation of their prodrugs. Nanoparticles of iron(iii) polycarboxylate Metal-Organic Frameworks (nanoMOFs) are promising drug nanocarriers. In this study, two active triphosphorylated NRTIs, azidothymidine triphosphate (AZT-Tp) and lamivudine triphosphate (3TC-Tp), were successfully co-encapsulated into the biocompatible mesoporous iron(iii) trimesate MIL-100(Fe) nanoMOF in order to improve anti-HIV therapies. The drug loaded nanoMOFs could be stored for up to 2-months and reconstituted after freeze drying, retaining similar physicochemical properties. Their antiretroviral activity was evidenced in vitro on monocyte-derived macrophages experimentally infected with HIV, making these co-encapsulated nanosystems excellent HIV-microbicide candidates.
Scientific Reports | 2017
Violeta Rodriguez-Ruiz; Andrey Maksimenko; Giuseppina Salzano; Maria Lampropoulou; Yannis G. Lazarou; Valentina Agostoni; Patrick Couvreur; Ruxandra Gref; Konstantina Yannakopoulou
Positively charged cyclodextrins (PCCDs) are molecular carriers of particular interest for their ability to readily enter into cancer cells. Of main interest, guanidino- and aminoalkyl- PCCDs can be conveniently synthesized and form stable and strong inclusion complexes with various active molecules bearing phosphate groups. We have addressed here the challenge to deliver into cancer cells phosphorylated gemcitabine drugs well known for their instability and inability to permeate cell membranes. NMR data corroborated by semiempirical theoretical calculations have shown that aminoalkyl-CDs form sufficiently stable complexes with both mono- and tri-phosphate forms of gemcitabine by simple mixing of the compounds in aqueous solution at physiological pH. Confocal microscopy and radioactivity counting experiments revealed that the developed systems enabled phosphorylated gemcitabine to penetrate efficiently into aggressive human breast cancer cells (MCF7), eventually leading to a substantial reduction of IC50 values. Moreover, compared to free drugs, phosphorylated metabolites of gemcitabine encapsulated in PCCDs displayed improved in vitro activities also on the aggressive human cancer cells CCRF-CEM Ara-C/8 C, a nucleoside transport-deficient T leukemia cell line. The current study offers the proof-of-principle that phosphorylated nucleoside drugs could be efficiently transported by PCCDs into cancer cells.
Scientific Reports | 2015
Valentina Agostoni; Patricia Horcajada; Magali Noiray; Milo Malanga; Ahmet Aykaç; L. Jicsinszky; Antonio Vargas-Berenguel; N. Semiramoth; S. Daoud-Mahammed; Valérie Nicolas; C. Martineau; F. Taulelle; J. Vigneron; A. Etcheberry; Christian Serre; Ruxandra Gref
Journal of Medicinal Chemistry | 2014
Maria Rosaria di Nunzio; Valentina Agostoni; Boiko Cohen; Ruxandra Gref; Abderrazzak Douhal
Photochemical and Photobiological Sciences | 2012
Resmi Anand; Francesco Manoli; Ilse Manet; Samia Daoud-Mahammed; Valentina Agostoni; Ruxandra Gref; Sandra Monti
Green Materials | 2013
Valentina Agostoni; Patricia Horcajada; Violeta Rodriguez-Ruiz; Hervé Willaime; Patrick Couvreur; Christian Serre; Ruxandra Gref
Biochimica et Biophysica Acta | 2017
Ahmet Aykaç; Magali Noiray; Milo Malanga; Valentina Agostoni; Juan M. Casas-Solvas; Éva Fenyvesi; Ruxandra Gref; Antonio Vargas-Berenguel